Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment

• Main Authors: Xu-Sheng Huang (Author), Ren-Rong Tian (Author), Meng-Di Ma (Author), Rong-Hua Luo (Author), Liu-Meng Yang (Author), Guang-Hui Peng (Author), Mi Zhang (Author), Xing-Qi Dong (Author), Yong-Tang Zheng (Author)
• Format: Book
• Published: MDPI AG, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Latent reservoir persistence remains a major obstacle for curing human immunodeficiency virus type 1 (HIV-1) infection. Thus, strategies for the elimination of latent HIV-1 are urgently needed. As a bromodomain and extra-terminal (BET) inhibitor, BMS-986158 has been used in clinical trials for advan...